Research agreement is evaluating feasibility of applying Rani’s oral delivery technology to Chugai’s antibodies against ...

Rani Therapeutics Holdings, Inc. has announced a research agreement with Chugai Pharmaceutical Co., Ltd. to evaluate the potential of Rani’s oral delivery technology, specifically the RaniPill ...

Rani Therapeutics announced positive preclinical data for RT-114 and semaglutide, advancing toward Phase 1 obesity trials in mid-2025. Rani Therapeutics Holdings, Inc. has announced preclinical ...

Rani Therapeutics (NASDAQ:RANI – Free Report) had its price target trimmed by Oppenheimer from $14.00 to $4.00 in a research note released on Friday,Benzinga reports.The brokerage currently has ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

SAN JOSE, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs ...

In a recent 8-K filing with the Securities and Exchange Commission, Rani Therapeutics Holdings , Inc., a Delaware-incorporated pharmaceutical company, announced entering into a significant ...

SAN JOSE, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage ...

May 19, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of ...

SAN JOSE, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs ...